Destiny Pharma's Neil Clark talks to Proactive's Katie Pilbeam about the 'depth' in its pipeline.
Clark talks about the potential XF-73 as a treatment for oral mucositis, one of the key side effects of chemotherapy.
He also mentioned new data on its XF-73 drug showing that it can boost the effectiveness of current standard of care antibiotics when used in combination.
That's in addition to finding a partner for the phase 3 trial of its NTCD-M3 biotherapeutic.